Pluristem Therapeutics Inc. (PSTI)

1.24
0.02 1.59
NASDAQ : Health Technology
Prev Close 1.26
Open 1.25
Day Low/High 1.22 / 1.26
52 Wk Low/High 1.06 / 2.12
Volume 127.23K
Avg Volume 286.00K
Exchange NASDAQ
Shares Outstanding 110.10M
Market Cap 132.12M
EPS -0.30
P/E Ratio 3.64
Div & Yield N.A. (N.A)

Latest News

Peer-Reviewed Article Published On Pluristem's PLX-PAD Cells' Mechanism Of Action To Restore Blood Flow In Ischemic Tissue

Peer-Reviewed Article Published On Pluristem's PLX-PAD Cells' Mechanism Of Action To Restore Blood Flow In Ischemic Tissue

Data supports advanced PLX-PAD clinical studies including dosing regimen, systemic therapeutic effects and superiority of the cells over cytokines

Pluristem Expands Its Reach In The Treatment Of Impaired Hematopoietic Systems With A European Patent Covering PLX-R18 In Chemotherapy, ARS, Genetic Disorders And Autoimmune Diseases

Pluristem Expands Its Reach In The Treatment Of Impaired Hematopoietic Systems With A European Patent Covering PLX-R18 In Chemotherapy, ARS, Genetic Disorders And Autoimmune Diseases

Patent significantly expands potential indications for PLX-R18 and grants Pluristem broad coverage in the treatment of damaged hematopoietic systems

FDA Grants Pluristem Orphan Drug Designation For Its PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome

FDA Grants Pluristem Orphan Drug Designation For Its PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome

Pluristem's ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.

TheStreet Quant Rating: D (Sell)